249 related articles for article (PubMed ID: 23996476)
1. Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management.
Belum VR; Cercek A; Sanz-Motilva V; Lacouture ME
Curr Treat Options Oncol; 2013 Sep; 14(3):389-404. PubMed ID: 23996476
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Eisen T; Sternberg CN; Robert C; Mulders P; Pyle L; Zbinden S; Izzedine H; Escudier B
J Natl Cancer Inst; 2012 Jan; 104(2):93-113. PubMed ID: 22235142
[TBL] [Abstract][Full Text] [Related]
3. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
Ravaud A
Oncologist; 2011; 16 Suppl 2(Suppl 2):32-44. PubMed ID: 21346038
[TBL] [Abstract][Full Text] [Related]
4. Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.
Belum VR; Washington C; Pratilas CA; Sibaud V; Boralevi F; Lacouture ME
Pediatr Blood Cancer; 2015 May; 62(5):798-806. PubMed ID: 25683226
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
[TBL] [Abstract][Full Text] [Related]
6. Emerging VEGF-receptor inhibitors for colorectal cancer.
Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.
Abrams TA; Meyer G; Schrag D; Meyerhardt JA; Moloney J; Fuchs CS
J Natl Cancer Inst; 2014 Feb; 106(2):djt371. PubMed ID: 24511107
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
9. Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists.
Ruiz JN; Belum VR; Creel P; Cohn A; Ewer M; Lacouture ME
Clin Genitourin Cancer; 2014 Oct; 12(5):341-7. PubMed ID: 25035283
[TBL] [Abstract][Full Text] [Related]
10. Highlights From: the 2006 American Society of Clinical Oncology Gastrointestinal Cancers Symposium San Francisco, CA, January 2006.
Gibson TB; Ranganathan A; D'Orazio A;
Clin Colorectal Cancer; 2006 Mar; 5(6):398-402. PubMed ID: 16635277
[No Abstract] [Full Text] [Related]
11. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
[TBL] [Abstract][Full Text] [Related]
12. How to Manage the Side Effects of New Targets Agents for Metastatic Colorectal Cancer.
Becze E
ONS Connect; 2016 Jan; 31(1):24-5. PubMed ID: 26887105
[No Abstract] [Full Text] [Related]
13. Chemotherapeutic agents and the skin: An update.
Heidary N; Naik H; Burgin S
J Am Acad Dermatol; 2008 Apr; 58(4):545-70. PubMed ID: 18342708
[TBL] [Abstract][Full Text] [Related]
14. [Targeted therapies for metastatic colorectal cancer].
Kito Y; Yamazaki K
Nihon Rinsho; 2015 Aug; 73(8):1384-90. PubMed ID: 26281694
[TBL] [Abstract][Full Text] [Related]
15. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
16. Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes.
Gill S; Dowden S; Colwell B; Collins LL; Berry S
Cancer Treat Rev; 2014 Dec; 40(10):1171-81. PubMed ID: 25458604
[TBL] [Abstract][Full Text] [Related]
17. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.
McLellan B; Ciardiello F; Lacouture ME; Segaert S; Van Cutsem E
Ann Oncol; 2015 Oct; 26(10):2017-26. PubMed ID: 26034039
[TBL] [Abstract][Full Text] [Related]
18. [Chemotherapy with molecular targeting agents for colorectal cancer].
Bando H; Ohtsu A
Nihon Rinsho; 2012 Nov; 70 Suppl 8():468-74. PubMed ID: 23513885
[No Abstract] [Full Text] [Related]
19. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
20. Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors.
Hofheinz RD; Segaert S; Safont MJ; Demonty G; Prenen H
Crit Rev Oncol Hematol; 2017 Jun; 114():102-113. PubMed ID: 28477738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
